+357 96 030922
info@marketpublishers.com

Global Sickle Cell Disease Treatment Market Size study, by Treatment (Blood Transfusion, Bone Marrow Transplant), by End-use (Hospitals, Specialty Clinics), and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G108851AF526EN.html
Date: May 2025
Pages: 285
Price: US$ 3,218.00 (Single User License)
ID: G108851AF526EN

Abstracts

Global Sickle Cell Disease Treatment Market is valued approximately at USD 2.75 billion in 2023 and is anticipated to grow with an accelerating compound annual growth rate of more than 15.70% over the forecast period 2024-2032. Sickle Cell Disease (SCD), a chronic and life-altering inherited blood disorder, has catalyzed a paradigm shift in the global healthcare ecosystem due to its profound clinical and socioeconomic implications. Characterized by abnormal hemoglobin structure causing red blood cells to deform and obstruct capillary circulation, SCD requires a multifaceted and highly responsive treatment approach. As disease awareness scales up and curative therapies transition from concept to clinic, the global sickle cell disease treatment market is navigating through a transformative phase, anchored by innovation in gene therapy, bone marrow transplants, and supportive transfusion-based care.

The ongoing evolution of the market is propelled by multiple converging forces. Firstly, a substantial rise in newborn screening programs and national registries is identifying cases earlier than ever before, enabling timely intervention. In parallel, governments across both developed and emerging economies are rolling out rare disease frameworks and funding initiatives for hematological conditions, paving the way for faster drug approvals and public reimbursement coverage. Furthermore, a robust pipeline of disease-modifying treatments—such as voxelotor and L-glutamine—are expanding therapeutic choices beyond conventional options like hydroxyurea. As the demand for definitive curative therapies rises, bone marrow transplants and gene-editing platforms such as CRISPR are gaining traction, offering the potential to redefine disease trajectories.

+357 96 030922
info@marketpublishers.com

Nevertheless, market growth faces notable impediments. High treatment costs and limited access to advanced therapeutics in low- and middle-income regions continue to hinder equitable care delivery. Additionally, donor compatibility remains a significant constraint for bone marrow transplants. However, to address these issues, public-private collaborations are emerging to subsidize treatment access, and research is underway to expand haploidentical transplant protocols that require less stringent matching. Stakeholders are also exploring digital tools for disease tracking, patient education, and remote consultations to reinforce patient adherence and minimize hospitalization costs.

A shift is underway toward decentralized care, where specialty clinics, mobile units, and outpatient hematology centers are beginning to take center stage. With blood transfusions still playing a vital role in crisis management and prophylaxis, supply chain efficiency is being bolstered by AI-driven inventory systems and smart blood matching technologies. Concurrently, the rise of gene therapy hubs in clinical research settings is reshaping long-term care strategies. Leading healthcare providers are also engaging in patient-centric outreach programs, helping increase treatment uptake and reducing societal stigma around chronic blood disorders.

Geographically, North America remains the frontrunner, driven by cutting-edge innovation, robust funding for orphan drug development, and strategic alliances between research institutions and biotech firms. Europe is also witnessing strong growth, particularly in countries like the UK, France, and Germany, where rare disease policies and early access schemes are fostering innovation. Meanwhile, the Asia Pacific region is poised for exponential growth over the forecast period due to increasing prevalence, improving diagnostic capabilities, and rising healthcare investments in countries such as India and China. Latin America and the Middle East & Africa are witnessing gradual adoption, supported by multinational healthcare collaborations, regional awareness campaigns, and donor-driven intervention programs.

Major market player included in this report are:

Novartis AG

Global Blood Therapeutics, Inc.

Pfizer Inc.

+357 96 030922
info@marketpublishers.com

Bluebird Bio, Inc.

Emmaus Medical, Inc.

CRISPR Therapeutics AG

Bristol-Myers Squibb Company

Vertex Pharmaceuticals Incorporated

Editas Medicine, Inc.

Sangamo Therapeutics, Inc.

Sanofi S.A.

Alnylam Pharmaceuticals, Inc.

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

The detailed segments and sub-segment of the market are explained below:

By Treatment

Blood Transfusion

Bone Marrow Transplant

By End-use

Hospitals

Specialty Clinics

+357 96 030922
info@marketpublishers.com

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

+357 96 030922
info@marketpublishers.com

Latin America

- Brazil
- Mexico

Middle East & Africa

- Saudi Arabia
- South Africa
- Rest of Middle East & Africa

Years considered for the study are as follows:

- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032

Key Takeaways:

- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market

+357 96 030922
info@marketpublishers.com

approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET EXECUTIVE SUMMARY

1.1. Global Sickle Cell Disease Treatment Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
  1.3.1. By Treatment
  1.3.2. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
  2.3.1. Inclusion & Exclusion
  2.3.2. Limitations
  2.3.3. Supply Side Analysis
    2.3.3.1. Availability
    2.3.3.2. Infrastructure
    2.3.3.3. Regulatory Environment
    2.3.3.4. Market Competition
    2.3.3.5. Economic Viability (Patient Perspective)
  2.3.4. Demand Side Analysis
    2.3.4.1. Rare Disease Frameworks & Policies
    2.3.4.2. Technological Advancements
    2.3.4.3. Healthcare Access & Awareness
    2.3.4.4. Patient Education & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET DYNAMICS

+357 96 030922
info@marketpublishers.com

3.1. Market Drivers
3.1.1. Expansion of Newborn Screening Programs
3.1.2. Government Rare Disease Frameworks & Funding Initiatives
3.1.3. Rise of Disease-Modifying Therapies (e.g., voxelotor, L-glutamine)
3.2. Market Challenges
3.2.1. High Treatment Costs & Economic Burden
3.2.2. Limited Access in Low- and Middle-Income Regions
3.2.3. Donor Compatibility Constraints for Transplants
3.3. Market Opportunities
3.3.1. Public–Private Collaborations for Subsidized Access
3.3.2. Advances in Haploidentical Transplant Protocols
3.3.3. Digital Health Tools for Disease Management & Remote Care

CHAPTER 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE & FORECASTS BY TREATMENT (2022–2032)

+357 96 030922
info@marketpublishers.com

5.1. Segment Dashboard
5.2. Global Market: Blood Transfusion Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.3. Global Market: Bone Marrow Transplant Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE & FORECASTS BY END-USE (2022–2032)

6.1. Segment Dashboard
6.2. Global Market: Hospitals Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.3. Global Market: Specialty Clinics Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE & FORECASTS BY REGION (2022–2032)

7.1. North America Market
  7.1.1. U.S. Market
    7.1.1.1. By Treatment breakdown size & forecasts, 2022–2032
    7.1.1.2. By End-use breakdown size & forecasts, 2022–2032
  7.1.2. Canada Market
7.2. Europe Market
  7.2.1. U.K. Market
  7.2.2. Germany Market
  7.2.3. France Market
  7.2.4. Spain Market
  7.2.5. Italy Market
  7.2.6. Rest of Europe Market
7.3. Asia Pacific Market
  7.3.1. China Market
  7.3.2. India Market
  7.3.3. Japan Market
  7.3.4. Australia Market
  7.3.5. South Korea Market
  7.3.6. Rest of Asia Pacific Market
7.4. Latin America Market

+357 96 030922
info@marketpublishers.com

7.4.1. Brazil Market
7.4.2. Mexico Market
7.4.3. Rest of Latin America Market
7.5. Middle East & Africa Market
7.5.1. Saudi Arabia Market
7.5.2. South Africa Market
7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Key Company SWOT Analysis
8.1.1. Novartis AG
8.1.2. Global Blood Therapeutics, Inc.
8.1.3. Pfizer Inc.
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Novartis AG
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Bluebird Bio, Inc.
8.3.3. Emmaus Medical, Inc.
8.3.4. CRISPR Therapeutics AG
8.3.5. Bristol-Myers Squibb Company
8.3.6. Vertex Pharmaceuticals Incorporated
8.3.7. Editas Medicine, Inc.
8.3.8. Sangamo Therapeutics, Inc.
8.3.9. Sanofi S.A.
8.3.10. Alnylam Pharmaceuticals, Inc.
8.3.11. Johnson & Johnson
8.3.12. Teva Pharmaceutical Industries Ltd.
8.3.13. Takeda Pharmaceutical Company Limited

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process
9.1.1. Data Mining

+357 96 030922
info@marketpublishers.com

9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Sickle Cell Disease Treatment Market Size study, by Treatment (Blood Transfusion, Bone Marrow Transplant), by End-use (Hospitals, Specialty Clinics), and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G108851AF526EN.html

Price: US$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G108851AF526EN.html